BIND Therapeutics
BIND Therapeutics: A new way of targeting disease
BIND: A NANOMEDICINE PLATFORM COMPANY DEVELOPING TARGETED THERAPEUTICS
 
At BIND, we seek to significantly improve patients' lives and treat disease by developing Accurins™, our novel targeted and programmable therapeutics.
BIND develops Accurins to outperform conventional drugs by selectively accumulating in diseased tissues and cells.
WHAT ARE ACCURINS?
 
Accurins are BIND's targeted and programmable therapeutics that are designed, utilizing our medicinal nanoengineering platform, with specified physical and chemical characteristics to target specific cells or tissues and concentrate a therapeutic payload at the site of disease to enhance efficacy while minimizing adverse effects on healthy tissues.
Learn more >
MEDICINAL NANOENGINEERING®
 
We develop Accurins using our proprietary Medicinal Nanoengineering platform that enables predictable, rapid design, characterization and optimization of our targeted and programmable nanomedicines.
Learn more >